Shionogi Enrolls the First Participant in Japan in its Global Phase 3 Trial of Ensitrelvir for the Prevention of Symptomatic SARS-CoV-2 Infection

Japanese pharmaceutical company Shionogi has enrolled the first participant in its global Phase 3 trial of Ensitrelvir, an oral antiviral designed to prevent symptomatic SARS-CoV-2 infection. The study will evaluate the drug's safety and efficacy in preventing infection among people exposed to household contacts who have tested positive for COVID-19. Approximately 2,200 participants across North..